Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26278412 | 0.95 | MEN1 (0.34) | KCNH2OPRM1OPRK1OGFRL1 | |
| SCHEMBL5271990 | 0.91 | MEN1 (0.37) | OPRM1OPRK1OGFRL1 | |
| SCHEMBL23951881 | 0.91 | MEN1 (0.37) | OPRM1OPRK1OGFRL1 | |
| SCHEMBL22969947 | 0.90 | OPRM1 (0.30) | OPRM1OPRK1OGFRL1 | |
| SCHEMBL12852095 | 0.90 | OPRM1 (0.30) | OPRM1OPRK1OGFRL1 | |
| SCHEMBL24637969 | 0.86 | KCNH2 (0.32) | KCNH2OPRM1OPRK1 | |
| SCHEMBL13629234 | 0.81 | TSHR (0.30) | — | |
| SCHEMBL8968088 | 0.80 | CHRNA7 (0.38) | KCNH2CHRNA7 | |
| SCHEMBL18180585 | 0.79 | SLC6A9 (0.37) | KCNH2OPRM1OPRK1OGFRL1CHRNA7 | |
| SCHEMBL12513920 | 0.79 | CRHBP (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023196930-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| WO-2023114733-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023105491-A1 | 5,6,7,8-TETRAHYDRO-2,6-NAPHTHYRIDINE DERIVATIVES AS CANCER THERAPEUTICS | VRISE THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023086383-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | 1200 PHARMA LLC (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023001123-A1 | NEW PYRIDOPYRIMIDINE DERIVATIVE | 上海艾力斯医药科技股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| WO-2022192598-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-0039903-B1 | 8-SUBSTITUTED PYRROLIZIDINES AND QUATERNARY AMMONIUM SALTS THEREOF | SUNTORY KABUSHIKI KAISHA (JP) | 1986-04-09 | — | — | EP | disclosed |
| US-4526969-A | Trifluoromethyl substituted perfluoro quinolizines | THE GREEN CROSS CORPORATION (JP) | 1985-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | KCNH2 3904/4885OPRM1 483/4885OPRK1 269/4885 |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KCNH2 4528/4885OPRM1 4469/4885OPRK1 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.